Loading…
Improving Development and Distribution of Diagnostic Tests Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2025 · second_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology Issues related to FDAs third party review program Issues related to the President's Emergency Program for AIDS Relief (PEPFAR)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $950,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2025 · first_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology Issues related to FDAs third party review program
Client expense: $1,042,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2024 · fourth_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology Issues related to FDAs third party review program
Client expense: $940,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2024 · third_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology HR 1328, the Medical Device Nonvisual Accessibility Act of 2023 Issues related to FDAs third party review program
Client expense: $960,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2024 · second_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology HR 1328, the Medical Device Nonvisual Accessibility Act of 2023 Issues related to FDAs third party review program
Client expense: $880,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2024 · first_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan Reimbursement and coverage of focused ultrasound technology HR 1328, the Medical Device Nonvisual Accessibility Act of 2023 Issues related to FDAs third party review program
Client expense: $1,030,000 · Firm income: Not reported
2023 · fourth_quarter · Health Issues
Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests VALID Act of 2023 - H.R. 2369. Issues related to Health Equity Issues related to Public Health Emergency Preparedness (including Pandemic All Hazards Preparedness Act reauthorization) Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 3723 - the Medical Device Electronic Labeling Act HR 5662/S 2907 - the Medical Device Recall Improvement Act S 2672 - Improving Development and Distribution of Diagnostic Tests Act HR 3795 - Diagnostic Testing Preparedness Plan
Client expense: $680,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office